Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This research study will test OT-82, which is an investigational ("research" or
"experimental" ) drug. The study has two stages (Stage 1 and Stage 2). The purpose of Stage 1
is to determine the safety and tolerability and the maximum tolerated dose (MTD) or the
maximum tested dose of OT-82 administered orally to participants. The purpose of Stage 2 is
to determine the preliminary efficacy of OT-82 in relapsed or refractory lymphoma at the MTD
or the maximum tested dose. Both parts of the study will also evaluate the pharmacokinetics
(absorption, distribution, metabolism, elimination) of OT-82.
OT-82 treatment slowed the growth, reduced the size, or in some cases cured certain cancers
in animal studies. It is hoped that participants with relapsed or refractory lymphoma treated
with OT - 82 in this study will experience slowing tumor growth and/or reduction of tumor
size.